Precigen Actobio

Foundation date

03/07/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.

Latest news

  • Waste2Func Video Release: The technology is ready, are we?

    Friday May 24th 2024

  • BIO INX and Readily3D Announce Collaboration to Advance Volumetric Bioprinting with Cutting-edge Gel-MA Based Ink

    Wednesday May 22nd 2024

  • Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®

    Wednesday May 22nd 2024